EN DE
Watch Axsome Therapeutics Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Axsome Therapeutics Inc (AXSM) stock: price, quality, comparison

Price, quality, revenue and earnings and the peer comparison for Axsome Therapeutics Inc, from audited financials.

Price: $132.37. No valuation: the company's figures do not support a reliable fair value right now, so we deliberately show none.
Price/sales 7.88× (industry 6.04×) · Revenue growth (quarter YoY) 51.9% (industry 0.0%)
  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

AT Axsome Therapeutics Inc logo Thin data Nov 7, 2026

Axsome Therapeutics Inc

AXSM · US
Positive coverage
Quality 43/100
Mixed Growth (revenue 3y +133.7 %/yr in USD)
Moderate debt
Insiders sold $48.9M (6M)
Loss-making · -18.2% net margin (TTM)
Negative free cash flow
Trails peers (1/8)
Narrow moat 13/100 · thin data
Thin data
No fair value
Watch Axsome Therapeutics Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Which stocks are undervalued right now? Check free Discover now →

Company profile

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.

Show moreShow less

The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura.

It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder.

It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.

Quality Score breakdown

Overall quality 43/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 34
How much profit the company makes from its sales and capital
Quality Growth 92
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 51
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 55
How calm the share price moves, does not count
Price momentum 18
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 16
Distance to the 52-week high, does not count
New shares 42
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 6 officers or directors sold shares worth $48.9M and none bought.

  • SaleMark L. JacobsonChief Operating Officer3× since Feb 26, 2026: 50,128 shares, avg. $177.47$8.9MSep 3, 202610b5-1 plan
  • SaleHerriot TabuteauChief Executive Officer, Director, 10% owner6× since Dec 2, 2025: 400,797 shares, avg. $189.59$76.0MAug 6, 202610b5-1 plan
  • SaleRoger JeffsDirector572 shares at $247.65$141,656Jun 11, 202610b5-1 plan
  • SaleMark ColemanDirector3× since Feb 26, 2026: 43,180 shares, avg. $190.07$8.2MJun 10, 202610b5-1 plan
  • SaleSusan MahonyDirector600 shares at $241.70$145,017Jun 10, 202610b5-1 plan
  • SaleNick PizzieChief Financial Officer2× since Jan 22, 2026: 45,000 shares, avg. $226.18$10.2MJun 9, 202610b5-1 plan
  • SaleAri MaizelChief Commercial Officer2× since Jan 21, 2026: 15,000 shares, avg. $183.43$2.8MApr 22, 202610b5-1 plan
  • SaleMark E SaadDirector37,577 shares at $165.18$6.2MDec 31, 202510b5-1 plan

Plus 9 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 29/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+65.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+133.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,413.9% (2021) → −26.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch AXSM, get fair value alerts →

Recent news

News mood ⓘNews mood, the average tone of recent news (96 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.

Compare Axsome Therapeutics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 559 stocks

Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 43 · Below median
Profitability
Return on assets −26.6% · Below median
Net margin (12 months) −18.2% · Below median
Operating margin (12 months) −5.2% · Below median
Growth and dividend
Revenue growth (quarter YoY) 51.9% · Top 25%
Balance sheet
Debt / equity 1.33× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/S (12 months) 7.88× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)33 · sector 97
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs AXSM
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs AXSM
Genmab A/S GMAB kr 3,527 kr 3,999 +13% vs AXSM
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$53.55 +12% vs AXSM
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs AXSM
Vertex Pharmaceuticals Incorporated VRTX $547.09 $596.75 +9% vs AXSM
argenx SE ARGX $927.21 $908.40 −2% vs AXSM
CSL Limited CSL A$202.04 A$183.04 −9% vs AXSM
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs AXSM
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs AXSM

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector

Frequently asked questions

What is the quality score of AXSM?
Axsome Therapeutics Inc has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Axsome Therapeutics Inc (AXSM)?
Axsome Therapeutics Inc reported trailing-twelve-month revenue of about $865M (latest available figure, as of Nov 7, 2026).
How solid is the balance sheet of Axsome Therapeutics Inc (AXSM)?
Balance-sheet figures for Axsome Therapeutics Inc (as of Nov 7, 2026): return on equity −175.6%, debt of 1.33 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
Which stocks are comparable to Axsome Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
What is the share price of Axsome Therapeutics Inc (AXSM)?
The closing price on Nov 6, 2026 was $132.37. We carry closing prices from our data provider, not a live tick.

Key figures of Axsome Therapeutics Inc

How large is the market capitalisation of Axsome Therapeutics Inc (AXSM)?
The market capitalisation of Axsome Therapeutics Inc is $6.8B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Axsome Therapeutics Inc (AXSM)?
The price-to-sales ratio of Axsome Therapeutics Inc is 8.48 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Axsome Therapeutics Inc (AXSM)?
Earnings per share at Axsome Therapeutics Inc are $−3.03. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Axsome Therapeutics Inc (AXSM)?
The net margin of Axsome Therapeutics Inc is −18.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Axsome Therapeutics Inc (AXSM)?
The return on equity (ROE) of Axsome Therapeutics Inc is −176% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Axsome Therapeutics Inc (AXSM)?
On an EBIT basis the return on assets of Axsome Therapeutics Inc is −61.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Axsome Therapeutics Inc (AXSM)?
The operating margin of Axsome Therapeutics Inc is −5.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Axsome Therapeutics Inc (AXSM)?
Revenue at Axsome Therapeutics Inc is growing +51.9% versus a year earlier (3y avg +134%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Axsome Therapeutics Inc (AXSM) generate?
The free cash flow of Axsome Therapeutics Inc is −$93.9M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Axsome Therapeutics Inc (AXSM) hold?
Axsome Therapeutics Inc holds more cash than debt, $81.6M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Axsome Therapeutics Inc in the live analysis

One click puts Axsome Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.